Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to ...
IRVING, Texas, July 27, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 3, …